Takeda Pharmaceutical Company Limited TAK
21.09 USD +0.07 (+0.33%)
At closeNov 10, 2026, 4:42 AM EST
20.88 -0.21 -1.00%
Pre-market · Nov 10, 4:42 AM ET
20.91 Day range 21.22
13.56 52-week range 21.73
- YTD
- +35.28%
- 1 year
- +53.83%
News
247wallst.com Most Investors Own VEA. Few Know About This International Cash Cows ETF VEA dominates international portfolios, but a smaller rival fund uses a completely different logic to pick foreign stocks, and over the past five years it has quietly beaten the giant on both returns…
benzinga.com Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.
benzinga.com Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript Takeda Pharmaceutical Co (NYSE:TAK) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is…
benzinga.com Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
benzinga.com Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.31 by 54.84 percent. This is a 20 percent increase over earnings of…
benzinga.com Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.- benzinga.com Takeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC Complication Risk By Nearly 70% Takeda ((TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF…
benzinga.com Ascentage Pharma Stock Could More Than Double: Analyst William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.- benzinga.com Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling − ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA)…